Manzo Pharmaceuticals, Inc. (OTCPink:MNZO) announced today that the company's President, Kenneth Manzo, has received a verbal Wells Notice from the US Securities and Exchange Commission.
Manzo Pharmaceuticals, Inc announced today that the company's President, Kenneth Manzo, has received a verbal Wells Notice from the US Securities and Exchange Commission.
Earlier from Manzo Pharmaceuticals
- Manzo Pharmaceuticals solidifies deal with USA based manufacturers to begin producing the company's lactose intolerance probiotic, Lacto-Freedom
- Manzo Pharmaceuticals Gets Remarkable Results On Human Study Of Lacto-Freedom™ For Lactose Intolerance As The Company Prepares For Production
- Manzo Pharmaceuticals starts human laboratory testing of the company's lactose intolerance probiotic, Lacto-Freedom™
- Manzo Pharmaceuticals announces exciting new product release as the company prepares for the full-scale human study of its Lacto-Freedom product to begin